InflaRx

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell InflaRx and other ETFs, options, and stocks.

About IFRX

InflaRx NV is a clinical-stage biopharmaceutical company, which engages in the discovery and development of inhibitors of the complement activation factor known as C5a and its receptor C5aR. Its primary product candidate is Vilobelimab. 

CEO
Niels Christoph Riedemann
CEONiels Christoph Riedemann
Employees
74
Employees74
Headquarters
Jena, Thueringen
HeadquartersJena, Thueringen
Founded
2007
Founded2007
Employees
74
Employees74

IFRX Key Statistics

Market cap
67.13M
Market cap67.13M
Price-Earnings ratio
-0.95
Price-Earnings ratio-0.95
Dividend yield
Dividend yield
Average volume
691.52K
Average volume691.52K
High today
$1.04
High today$1.04
Low today
$1.00
Low today$1.00
Open price
$1.00
Open price$1.00
Volume
94.66K
Volume94.66K
52 Week high
$2.77
52 Week high$2.77
52 Week low
$0.7113
52 Week low$0.7113

Stock Snapshot

With a market cap of 67.13M, InflaRx(IFRX) trades at $1.00. The stock has a price-to-earnings ratio of -0.95.

During the trading session on 2026-01-14, InflaRx(IFRX) shares reached a daily high of $1.04 and a low of $1.00. At a current price of $1.00, the stock is 0.0% higher than the low and still -3.8% under the high.

Trading volume for InflaRx(IFRX) stock has reached 94.66K, versus its average volume of 691.52K.

Over the past 52 weeks, InflaRx(IFRX) stock has traded between a high of $2.77 and a low of $0.71.

Over the past 52 weeks, InflaRx(IFRX) stock has traded between a high of $2.77 and a low of $0.71.

IFRX News

TipRanks 6d
InflaRx Cuts Workforce and Refocuses Strategy on Lead Drug Izicopan to Extend Cash Runway to 2027

Claim 70% Off TipRanks Premium InflaRx ( (IFRX) ) has shared an update. On January 8, 2026, InflaRx announced a strategic realignment that sharply prioritizes...

TipRanks 6d
InflaRx to prioritize izicopan as lead asset, reduces workforce by 30%

InflaRx (IFRX) is undertaking measures to reduce spending, extend the Company’s cash runway, and align resources to enable further development of izicopan in HS...

Analyst ratings

75%

of 8 ratings
Buy
75%
Hold
25%
Sell
0%

People also own

Based on the portfolios of people who own IFRX. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the .